Donanemab-AZBT Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Donanemab-AZBT Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
20
Registered trials
23
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Donanemab-AZBT can convert its Monoclonal antibody profile and pGlu3Aβ biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Donanemab-AZBT (query alias: Donanemab-AZBT) |
|---|---|
| Modality / target | Monoclonal antibody; pGlu3Aβ; 3pE-modified Aβ inhibitors |
| Highest global status | Approved |
| Originator | Eli Lilly & Co. |
| Active developers | Eli Lilly & Co., Eli Lilly Nederland BV, Eli Lilly Canada, Inc. |
The MCP disease footprint includes Nervous System Diseases, Dementia due to Alzheimer's disease (disorder), Mild cognitive disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07602582 | Phase 3 | Recruiting | 550 | Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) |
| NCT07571161 | Phase 3 | Recruiting | 140 | Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS) |
| NCT07589595 | Phase 2 | Recruiting | 350 | Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease
Phase 2; n=251; evaluation: Positive. Reported fields: ADCS-ADL(76-week) = -0.14 Point
Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults With Early Symptomatic Alzheimer's Disease
Phase 3; n=1175; evaluation: not stated. Reported fields: -; Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) = 18.31 Percentage of participants ; Percentage of Participants With Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) = 23.67 Percentage of participants
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: ARIA-E frequency = 24.2 % ; ARIA-E frequency = 15.6 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Donanemab-AZBT addresses Nervous System Diseases, Dementia due to Alzheimer's disease (disorder), Mild cognitive disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: pGlu3Aβ records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-12-19 | BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program | Preclinical | US$100.0M upfront; US$1,250.0M milestones |
| 2024-10-28 | AbbVie, Inc. acquires Aliada Therapeutics, Inc. | Phase 1 | US$1,400.0M stated total |
| 2021-06-29 | Simcere to collaborate with Vivoryon in the development and commercialization of PQ-912 and PBDC-06 for Alzheimer's disease in Greater China, including China, Hong Kong, Macau, and Taiwan. | Not disclosed | US$565.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
